LGM Pharma Acquires Sannova Analytical

LGM Pharma, a provider of tailored API sourcing, contract analytical testing, and drug development services, has acquired Sannova Analytical, a contract research laboratory headquartered in Somerset, NJ.

The acquisition expands LGM Pharma’s analytical testing services business by adding Good Laboratory Practice (GLP) bioanalysis, including peptide and oligonucleotide testing, and by bringing genotoxic and nitrosamine impurity testing, extractables and leachables evaluations, and additional elemental impurities testing to LGM Pharma’s existing cGMP analytical services. Sannova will continue to operate under its own name, led by its current management team.

Reasons for the Acquisition

The acquisition is part of LGM Pharma’s strategy to build a U.S.-based analytical services platform alongside its API sourcing business. In line with this strategy, the company announced Texas and Colorado investments earlier this year.

“Over the last five years, we’ve built analytical testing into a standalone business, and the two things our clients keep asking for are bioanalysis and more extensive impurity work,” said Prasad Raje, Ph.D., CEO of LGM Pharma. “Sannova gives us both, along with a U.S.-based team that develops and validates its methods at the center of the Northeast pharmaceutical corridor. This acquisition provides additional capabilities, but it also adds capacity for the growing volume of work our clients are bringing to us.”

Sannova clients will keep the same scientific team, qualified methods, and contacts they work with today, and gain access to LGM Pharma’s API sourcing and its regulatory and market intelligence services. LGM Pharma clients will gain a cGMP analytical laboratory in the Northeast corridor, along with GLP bioanalytical services and analytical testing available throughout the U.S.

The acquisition gives clients a single partner for API sourcing, release and stability testing of APIs and drug products, and bioanalysis, whether they are manufacturers working through nitrosamine drug substance-related impurity (NDSRI) risk assessments or biotech teams moving a program from preclinical studies through Phase 4.

“Our clients chose Sannova for the people and methods behind their data, and those stay in place,” said Malleswar Kollu, president and CEO of Sannova Analytical. “LGM Pharma’s backing lets us continue investing in our scientists, instruments, capacity, and client services faster than we could independently.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.